Adaptive Biotechnologies ADPT Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's accounts receivable?
- Adaptive Biotechnologies (ADPT) reported accounts receivable of $48.32M in Q1 2026.
- How has Adaptive Biotechnologies's accounts receivable changed year-over-year?
- Adaptive Biotechnologies's accounts receivable increased by 10.9% year-over-year, from $43.58M to $48.32M.
- What is the long-term trend for Adaptive Biotechnologies's accounts receivable?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's accounts receivable has grown at a 38.0% compound annual growth rate (CAGR), from $10.05M to $50.37M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.